PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Merck to donate vaccine doses to IAVI for Sudan ebola virus

Merck & Co – known as MSD outside the US and Canada – has announced that, in response to the Sudan Ebola virus outbreak in Uganda, it is planning to produce and donate doses of its investigational Sudan Ebola virus vaccine candidate to the International AIDS Vaccine Initiative (IAVI), a global nonprofit scientific research organisation, for further clinical research use.

Merck said it expects to provide about 50,000 doses to IAVI by the end of 2022 and is working with the organisation towards a formal agreement.

The doses will be produced from the existing investigational bulk drug substance previously manufactured by Merck and are intended to be used as part of the World Health Organization’s (WHO’s) efforts to fight the outbreak in Uganda.

There have been more than 90 confirmed and probable cases of Ebola in Uganda since the start of the outbreak, including at least 44 deaths, according to WHO.

“We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of WHO and the people of Uganda as they grapple with this outbreak,” said Beth-Ann Coller, executive director, of global clinical development vaccines, Merck Research Laboratories.

The virus circulating in Uganda is the Sudan strain of Ebola, for which there is no proven vaccine, unlike the Zaire strain that has been the most common cause of Ebola outbreaks over the past 20 years.

The doses use a replication-competent, live, attenuated recombinant vesicular stomatitis virus vaccine construct, which is similar to that used for Merck’s Ervebo vaccine.

The Ervebo vaccine is approved in the UK, the EU, the US, Switzerland, and ten countries in Africa as a single dose for adults 18 years and older, to protect against the Zaire Ebola virus.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026